Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab

Recently, the superiority of atezolizumab plus bevacizumab (AteBeva) over sorafenib was proven in the IMbrave150 trial, and AteBeva became the first-line systemic treatment for untreated, unresectable hepatocellular carcinoma (HCC). While the results are encouraging, more than half of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yong Tae, Kim, Jina, Seong, Jinsil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Liver Cancer Association 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202242/
https://www.ncbi.nlm.nih.gov/pubmed/37384021
http://dx.doi.org/10.17998/jlc.2023.02.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202242/
https://www.ncbi.nlm.nih.gov/pubmed/37384021
http://dx.doi.org/10.17998/jlc.2023.02.27

Ejemplares similares